Thromboembolic events troublesome for Lilly lung cancer drug
This article was originally published in Scrip
Executive Summary
An increased number of thromboembolic events (TE) observed in trials of Lilly's experimental non-small-cell lung cancer (NSCLC) drug necitumumab may mean trouble for the firm's biologics license application (BLA) when it goes before the FDA's Oncologic Drugs Advisory Committee (ODAC) on 9 July.